Novo Nordisk has multiple weight-loss drugs in various stages of development and approval, according to its R&D pipeline. These include, among others, monlunabant (phase 2); oral and subcutaneous ...

Pharmaceutical vending machine at an airport. Image by Tim Sandle. Pharmaceutical vending machine at an airport. Image by Tim Sandle. Can a new discovery usher in a new generation of GLP-1 peptides – ...

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).

Explore the benefits of the Precision GLP-1 agonist, a new therapy that improves glycaemic control and reduces side effects.

So many options. So much noise. Here's what to know about GLP-1s now.

SYDNEY, AUSTRALIA - JANUARY 13: Ozempic is medicine for adults with type 2 diabetes . Wegovy is prescribed for long-term weight loss in adults and children. Both contain the active ingredient ...

Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.

Opportunities in the GLP-1 receptor agonist market include the development of new diabetes and obesity treatments with high ...

Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most effective weight loss medication yet. Retatrutide is a triple-agonist ...

Add Yahoo as a preferred source to see more of our stories on Google. Eli Lilly, which makes Zepbound and Mounjaro, just announced phase 3 clinical trial results for its new medication, retatrutide, ...